Suche

Cinqaero

reslizumab · R03DX08

Eosinophile Erkrankungen (ICD‑10 D72.1) Differenzialdiagnostik & Therapie‑Standard

Eosinophile Erkrankungen umfassen eine heterogene Gruppe von Krankheitsbildern, bei denen eosinophile Granulozyten im peripheren Blut und/oder Geweben pathologisch erhöht sind. Die Prävalenz variiert stark je nach Subtyp; beispielsweise …

Cinqaero · 4.5 · No formal clinical interaction studies have been performed with reslizumab. In vitro data indicate that IL-5 a

Cinqaero · 4.5 · Reslizumab has not been studied in patients concurrently taking immunosuppressant medicinal products other tha

Cinqaero · 4.5 · Reslizumab has not been studied in patients receiving live vaccines. No data are available on the secondary tr

Cinqaero · 4.8 · In placebo-controlled clinical studies, 6 out of 1,028 patients (0.6%) receiving 3 mg/kg reslizumab had at lea

Cinqaero · 4.8 · Myalgia Myalgia was reported in 0.97% of patients (10 out of 1,028) in the 3 mg/kg reslizumab group of the pla

Cinqaero · 4.8 · The following adverse reactions have been reported with reslizumab during placebo-controlled asthma studies fo